Eli Lilly's New Weight Loss Drugs Could Strengthen Its Market Position Against Novo Nordisk
Novo Nordisk is trying to regain its market edge by launching a pill-based version of Wegovy, but Eli Lilly continues to lead with strong Zepbound sales and the upcoming launch of more advanced drugs. The pharmaceutical giant's new triple agonist drug candidate could further solidify its position in the GLP-1 weight loss space.
Topics: Eli Lilly vs. Novo Nordisk GLP-1 drugs weight loss medications